Supporting pharmaceutical and biotechnology teams at early development and CMC decision points — where choices are visible to regulators and expensive to reverse.
Senthil Murugappan
Helion is led by Senthil Murugappan, PhD, a senior development and CMC professional with 10+ years of hands‑on experience across vaccines, biologics, mRNA, and novel delivery platforms. He has led formulation, stabilisation, and CMC strategy from preclinical through early clinical and platform programs, including microneedle‑based vaccine delivery.
His work centres on early technical judgement, risk identification, and decision clarity at the points where development pathways become hard and expensive to change—helping biotech leaders make confident calls on CMC, formulation, and platform choices when it matters most.
Most programs don't fail because the science is weak; they run into trouble because early CMC, formulation, or platform decisions were never fully stress‑tested—and only show up as problems when timelines, capital, and reputation are already on the line.
Helion exists to improve decision quality at development inflection points: preparing for first‑in‑human, choosing or locking into a delivery platform, committing to a formulation, or stepping into a major BD or financing process. These are the moments where "small" compromises quietly compound into disproportionate regulatory and CMC risk later.
In practice, that means taking complex detail at the interface of science, safety, formulation, and strategy and turning it into clear options and trade‑offs that CEOs, boards, and investors can confidently stand behind.
All implementation and final regulatory responsibility remains with the client. Helion provides independent judgement and decision support, not implementation.
Specialised in Complex Programs
Supporting early-stage programs in translating discovery assets into credible, regulator-ready development strategies for first-in-human programs.
Stability-led formulation strategy aligned with delivery route, scale-up, and regulatory expectations.
Independent CMC judgement to support internal decisions, investor confidence, and business development activity.
Advising on emerging and advanced delivery platforms — separating technical reality from marketing claims. Experience includes microneedle systems, nasal and pulmonary delivery, and biologic/device combination products.
Preparing for first-in-human studies
Transitioning from discovery to development
Selecting or committing to a delivery platform
Facing formulation or comparability uncertainty
Supporting BD or investment decisions
"We'll fix it in the next phase..."
Formulation or analytical choices treated as temporary.
Development logic being retrofitted to existing data.
Regulatory questions focusing on consistency rather than gaps.
Helion works through clearly framed, fixed‑scope advisory projects built around specific decisions—no open‑ended hourly billing, no vague mandates. You know in advance what we will do, what you will receive, how long it will take, and what it will cost.
Typical engagements include:
Each assessment is time‑boxed (usually 4–6 weeks) and anchored on a clear decision you need to make.
Independent judgement only. No execution services, no labs, no manufacturing.
Details →Clear objectives, questions, and deliverables agreed before we start.
Details →Complete discretion, with sensitive information handled to the highest standard.
Details →You stay in control. Final decisions remain with your team.
Details →
The most damaging CMC issues rarely announce themselves at preclinical stage. They accumulate quietly in decisions that seem rational in isolation but create compound risk over time.
Read →
Too many early-stage programs treat formulation as something resolved by the CRO during scale-up. By then, the decisions have already been made — just not by you.
Read →
Delivery platform selection often happens under commercial pressure with limited independent technical scrutiny. The gap between what platforms claim and what they can demonstrably deliver remains significant.
Read →Insights are published selectively and are not intended as regulatory or legal advice.
Helion Advisory Group provides independent technical judgement and advisory services only. Helion does not provide regulatory sign-off, execution services, or manufacturing activities. All development, regulatory, and implementation decisions remain the responsibility of the client.
Strategic engagements are managed with strict discretion. Reach out directly for technical briefing or program-level requirements.
We will respond within 24 business hours.
